Gerresheimer warns accounting probe will impact 2025 results as company sells US business

Gerresheimer expects an accounting probe to hit 2025 results and is selling its US unit. The firm delayed its report after finding internal rule violations.

洞察:
Gerresheimer AG announced today that an expanded internal investigation into its accounting practices will materially affect its 2025 financial results. The company, which is based in Germany DEDE, has engaged a second auditing firm to conduct a thorough review of revenue recognition and accounting procedures for both the 2024 and 2025 fiscal years. This ongoing probe has forced the manufacturer to delay its scheduled results publication, which was originally set for February 26, while also prompting a significant downgrade of its 2025 outlook for revenue, EBITDA-margin, and adjusted earnings per share (EPS).
Vials produced by Gerresheimer are displayed at the annual Drug, Chemical & Associated Technologies Association (DCAT) week in New York City, U.S. March 19, 2024. REUTERS/Patrick Wingrove
Vials produced by Gerresheimer are displayed at the annual Drug, Chemical & Associated Technologies Association (DCAT) week in New York City, U.S. March 19, 2024. REUTERS/Patrick Wingrove